Eli Lilly in advanced clinical trials for its weight-loss pill
Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess its safety and efficacy compared to insulin glargine in individuals with type-two diabetes and obesity or overweight at an increased cardiovascular risk. The company's spokesperson in India mentioned ongoing clinical studies on novel products, including orforglipron.
Source: The Economic Times - Category: Consumer Health News Source Type: news
More News: Cardiology | Cardiovascular | Clinical Trials | Diabetes | Eating Disorders & Weight Management | Endocrinology | Health | Heart | India Health | Insulin | Lantus | Men | Obesity | Study | Weight Loss